Keyphrases
Pediatric Intensive Care Unit
100%
Respiratory Syncytial Virus
100%
Intensive Care Unit Admission
100%
Retrospective multicenter Study
100%
Respiratory Syncytial Virus Infection
37%
Palivizumab Prophylaxis
37%
Airway
25%
Neuromuscular Disease
25%
Congenital Abnormalities
25%
Clinical Outcomes
12%
Risk Factors
12%
High Risk
12%
Health Care Costs
12%
Hospitalization
12%
Prematurity
12%
Clinical High Risk
12%
Common Risk Factors
12%
Ventilation Rate
12%
March 2013
12%
Retrospective Chart Review
12%
Congenital Heart Disease
12%
Intensive Care Unit Stay
12%
Chronic Lung Disease
12%
Attributable Mortality
12%
Palivizumab
12%
Hemodynamically Significant
12%
Intensive Care Unit Care
12%
Medicine and Dentistry
Intensive Care
100%
Intensive Care Unit
100%
Human Respiratory Syncytial Virus
100%
Palivizumab
50%
Respiratory Syncytial Virus Infection
37%
Congenital Disorder
25%
Neuromuscular Disease
25%
Health Care Cost
12%
Prematurity
12%
Artificial Respiration
12%
Chronic Lung Disease
12%
Persistent Truncus Arteriosus
12%
Pharmacology, Toxicology and Pharmaceutical Science
Human Respiratory Syncytial Virus
100%
Palivizumab
80%
Respiratory Syncytial Virus Infection
60%
Congenital Disorder
40%
Neuromuscular Disease
40%
Prematurity
20%
Congenital Heart Disease
20%
Chronic Lung Disease
20%
Immunology and Microbiology
Human Respiratory Syncytial Virus
100%
Palivizumab
80%
Respiratory Syncytial Virus Infection
60%